Delivery Order SPE2DB25D3404-SPE2DB26FULSU
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 15, 2025, for Prolia 60 mg/mL syringes valued at $12,957.22. The contract employs firm fixed pricing with an ultimate completion date of September 16, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, valued at $9,104.04 under firm fixed price terms. The award, issued on August 7, 2025, with completion targeted for August 8, 2025, represents a child delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $16,071.75 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $32,625.43 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, non-set-aside contract executed on August 19, 2025, with performance to take place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $26,999.75 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed price contract is non-competitive with no set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $59,815.89 by the Defense Logistics Agency (DLA) on September 22, 2025. The contract, designated as a firm fixed-price delivery order with no set-aside, calls for the supply of Prolia 60 mg/mL syringes and is scheduled for completion by September 23, 2025. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $39,328.20 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Prolia 60 mg/mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $15,697.68 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 4, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,113.51 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's broader relationship with the federal government as a major...
- The Defense Logistics Agency awarded a $4,604.95 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, with an ultimate completion date of August 28, 2025. This firm fixed-price contract, issued on August 27, 2025, represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB26FULSUDelivery Order
The Defense Logistics Agency awarded a $8,547.16 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, with an ultimate completion date of October 21, 2025. This non-competitive, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a primary pharmaceutical distributor for federal medical procurement. This delivery order falls within AmerisourceBergen's established role as a critical pharmaceutical vendor supporting military and veteran healthcare systems. Prolia (denosumab) is a biologic medication used to treat osteoporosis and bone loss conditions, consistent with the company's extensive portfolio of specialty medications supplied through the DLA's global pharmaceutical support program. The firm fixed-price structure and delivery order mechanism reflect the efficiency of the underlying IDC vehicle, which enables rapid procurement of essential pharmaceutical products across the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 10/20/25 |